|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||17.50 - 17.50|
|52-week range||15.96 - 26.29|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||60.34|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||03 June 2021|
|1y target est||N/A|
On top of those pluses, these three companies all have a history of offering above-average dividends, making them solid long-term value bargains. Takeda is a Japanese biopharmaceutical company that focuses on gastroenterology, oncology, neuroscience, and rare diseases. The company's stock is up more than 9% this year, currently trading at just shy of $15.
With stratospheric market caps and a plodding pace of expansion, it's easy to see why many growth investors eschew them for smaller, nimbler biotechs that have the potential to multiply in value overnight. Both of the healthcare stocks I'll discuss pay a dividend that's higher than the market's average yield of 1.27%, but their real advantage is that they make medicines that patients and healthcare systems are going to need more or less forever. Grifols (NASDAQ: GRFS) makes plasma-derived medicines that are necessary for a variety of hospital procedures ranging from cardiopulmonary bypasses to rehydration, generating trailing revenue of $5.2 billion in the process.
Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.